The purpose of this research resource application (R24) is to provide support for the establishment of a canine blood disease models and stem cell (CBDSC) resource. The purpose of the canine blood disease models and stem cell resource is to maintain canine models of hemophilia A, hemophilia B, pyruvate kinase (PK) deficiency and cyclic hematopoiesis (CH), provide experimental animals for hematology research and to provide canine blood, bone marrow, peripheral blood stem cells (PBSCs), hematopoietic progenitor and stem cells and technical expertise with the canine model. The objectives of this research resource grant are: (1) maintain breeding colonies of hemophilia, PK and CH dogs;(2) provide purpose bred experimental animals for collaborative investigation;and (3) provide canine blood and bone marrow stem cells, tissues and canine-validated reagents, and assays to qualified investigators. The canine models have been maintained in the principal investigator's laboratory for up to 20 years and have been used in collaborative studies with NIH funded investigators at multiple institutions but have not been universally available. The hemophilia B model is uniquely prone to developing inhibitors making it ideal for gene therapy and tolerance studies. The PK deficient dogs are not available elsewhere and the hemophilia A and CH dogs are only available in very limited numbers at 1 other institution. Dog leukocyte antigen (DLA), histocompatability typing of the breeding colony and experimental animals has been established so that DLA identical, haploidentical and mismatched dogs are used in transplantation studies. The dog is a well established preclinical model for bone marrow transplantation, cardiac and hemophilia research. Although there are numerous NIH supported primate and rodent resources there presently is not a centralized canine resource to provide cells, tissues , reagents and specialized support services as a research resource for investigators using the canine model. The investigators have more than 30 years combined experience with canine blood disease research and are uniquely qualified to establish a canine blood disease and stem cell resource. This project will ensure the survival of unique canine blood disease models, provide broader access to the models by qualified investigators and establish a centralized resource for canine blood and stem cells to address unmet needs in biomedical research community.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Resource-Related Research Projects (R24)
Project #
5R24HL086944-03
Application #
7647942
Study Section
Special Emphasis Panel (ZHL1-CSR-A (M2))
Program Officer
Link, Rebecca P
Project Start
2007-07-01
Project End
2012-06-30
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
3
Fiscal Year
2009
Total Cost
$314,402
Indirect Cost
Name
University of Alabama Birmingham
Department
Biochemistry
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
French, Robert A; Samelson-Jones, Benjamin J; Niemeyer, Glenn P et al. (2018) Complete correction of hemophilia B phenotype by FIX-Padua skeletal muscle gene therapy in an inhibitor-prone dog model. Blood Adv 2:505-508
Sun, Junjiang; Shao, Wenwei; Chen, Xiaojing et al. (2018) An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Mol Ther Methods Clin Dev 10:257-267
Crudele, Julie M; Finn, Jonathan D; Siner, Joshua I et al. (2015) AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice. Blood 125:1553-61
Vallejo, Matthew O; Niemeyer, Glenn P; Vaglenov, Alex et al. (2013) Decreased hematopoietic progenitor cell mobilization in pearl mice. Exp Hematol 41:848-57
Meng, Ronghua; Bridgman, Roger; Toivio-Kinnucan, Maria et al. (2010) Neutrophil elastase-processing defect in cyclic hematopoietic dogs. Exp Hematol 38:104-15
Monahan, Paul E; Lothrop, Clinton D; Sun, Junjiang et al. (2010) Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application. Mol Ther 18:1907-16
Niemeyer, Glenn P; Herzog, Roland W; Mount, Jane et al. (2009) Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood 113:797-806